Mouth Neoplasms: Clinical Trials

374 completed, 122 recruiting, 104 unknown, 59 terminated. 246 Phase 2, 183 Not applicable, 136 Phase 1, 52 Phase 3, 13 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	246	Completed 121, Recruiting 33, Active not recruiting 32, Terminated 27, Unknown 20, Not yet recruiting 7, Withdrawn 5, Suspended 1
Not applicable	183	Completed 82, Recruiting 43, Unknown 28, Not yet recruiting 13, Terminated 6, Withdrawn 5, Active not recruiting 4, Enrolling by invitation 2
Phase 1	136	Completed 78, Terminated 17, Recruiting 14, Active not recruiting 13, Withdrawn 8, Unknown 4, Not yet recruiting 1, Suspended 1
Phase 3	52	Completed 24, Unknown 9, Active not recruiting 5, Recruiting 5, Not yet recruiting 4, Terminated 3, Withdrawn 2
Early Phase 1	13	Completed 3, Recruiting 3, Unknown 3, Terminated 2, Active not recruiting 1, Not yet recruiting 1
Phase 4	11	Completed 5, Recruiting 2, Unknown 2, Active not recruiting 1, Terminated 1

Follow Mouth Neoplasms: new trials by email Literature Review of Mouth Neoplasms trials Research Report on Mouth Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma	Phase 2	Withdrawn	Actuate Therapeutics Inc.		2030-12-18	2022-02-22
Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy Osteoradionecrosis, Radiotherapy		Not yet recruiting	AO Innovation Translation Center	1000	2027-03-01	2026-09-23
Sac-TMT in Salivary Gland Cancers Sacituzumab Tirumotecan (Sac-TMT) - Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary Gland	Phase 2	Not yet recruiting	Latin American Cooperative Oncology Group	64	2027-03-01	2026-11-10
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 1	Recruiting	National Cancer Institute (NCI)	39	2027-02-13	2026-10-29
Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage Deep UV-M and AI Cytology Triage - Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders	Not applicable	Not yet recruiting	Anh Le	270	2026-12-01	2026-09-25
Oral Cancer Awareness in Egypt Questionnaire - Oral Cancer		Not yet recruiting	Ayat Gamal-AbdelNaser	1844	2026-12-01	2026-09-29
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma	Phase 1 / Phase 2	Not yet recruiting	Washington University School of Medicine	45	2026-11-30	2026-11-03
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma	Phase 1 / Phase 2	Recruiting	National Cancer Institute (NCI)	120	2026-11-18	2026-11-13
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) Nivolumab-IRDye800 - HNSCC, SCC - Squamous Cell Carcinoma	Early Phase 1	Recruiting	Vanderbilt-Ingram Cancer Center	18	2026-10-30	2026-11-12
LIMA1 Immunohistochemistry and Depth of Invasion as Prognostic Biomarkers in Oral Squamous Cell Carcinoma Oral Squamous Cell Carcinoma (OSCC), OSCC		Enrolling by invitation	Turku University Hospital	140	2026-10-19	2026-11-12
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma	Phase 3	Not yet recruiting	caohaotian	300	2026-10-01	2026-09-18
Abiraterone With Dalpiciclib in Salivary Gland Carcinoma abiraterone combined with dalpiciclib - Salivary Gland Carcinoma	Phase 2	Recruiting	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	36	2026-10-01	2026-09-11
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers Salivary IL-8 and Serum IL-6 Measurement - Oral Potentially Malignant Disorders, Oral Lichen Planus		Recruiting	British University In Egypt	250	2026-10-01	2026-11-04
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)	Phase 1	Recruiting	Metaclipse Therapeutics Corporation	30	2026-10-01	2026-10-27
Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers Electronic Health Record Review, Fentanyl, Laryngoscopy - Head and Neck Carcinoma, Hypopharyngeal Carcinoma	Phase 4	Recruiting	OHSU Knight Cancer Institute	58	2026-09-22	2026-10-05
Rehabilitation Through Individualized Support and Exercise Tailored physiotherapy program for early mobilization after oral cancer surgery - Oral Cancer, Head and Neck Cancer	Not applicable	Not yet recruiting	Universitaire Ziekenhuizen KU Leuven	39	2026-09-10	2026-10-05
Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions 5-Amino Levulinic Acid - Oral Cancer, Oral Cavity Cancer	Phase 2	Not yet recruiting	University of Massachusetts, Boston	65	2026-09-01	2026-03-19
Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma	Phase 1	Recruiting	Erasmus Medical Center	30	2026-09-01	2026-09-02
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma	Early Phase 1	Not yet recruiting	Lumina Pharmaceuticals Inc	40	2026-09-01	2026-08-28
Effects of a Perma-h Model Mobile-based Rehabilitation Support Program on Hope, Self-efficacy, Perceived Social Support and Rehabilitation Outcomes in Post- Tracheostomy Oral Cancer Patients PERMA-H model mobile-based rehabilitation support program - Tracheostomized Patients, Decanulation	Not applicable	Not yet recruiting	Hainan Medical College	100	2026-08-01	2026-07-20

Showing 20 of 776. Sign in to see all of them.

Narrower conditions

Squamous Cell Carcinoma of Head and Neck (275)  ·  Head and Neck Neoplasms (255)  ·  Salivary Gland Neoplasms (240)  ·  Oropharyngeal Neoplasms (137)  ·  Tongue Neoplasms (121)  ·  Laryngeal Neoplasms (109)  ·  Hypopharyngeal Neoplasms (92)  ·  Carcinoma, Non-Small-Cell Lung (67)  ·  Breast Neoplasms (66)  ·  Esophageal Neoplasms (54)  ·  Lung Neoplasms (51)  ·  Pancreatic Neoplasms (51)  ·  Nasopharyngeal Neoplasms (50)  ·  Stomach Neoplasms (49)

Broader conditions

Stomatognathic Diseases (775)  ·  Neoplasms by Site (772)  ·  Mouth Diseases (769)  ·  Neoplasms (733)  ·  Head and Neck Neoplasms (521)  ·  Neoplasms by Histologic Type (375)  ·  Neoplasms, Glandular and Epithelial (366)  ·  Carcinoma (331)  ·  Salivary Gland Diseases (269)  ·  Carcinoma, Squamous Cell (255)  ·  Otorhinolaryngologic Diseases (187)  ·  Respiratory Tract Diseases (181)  ·  Pharyngeal Diseases (176)  ·  Otorhinolaryngologic Neoplasms (174)

Interventions

Cisplatin (60)  ·  Radiotherapy (37)  ·  Cetuximab (32)  ·  Magnetic Resonance Spectroscopy (28)  ·  Radiotherapy, Intensity-Modulated (27)  ·  Docetaxel (26)  ·  pembrolizumab (26)  ·  Biopsy (24)  ·  Carboplatin (24)  ·  Specimen Handling (21)  ·  Paclitaxel (20)  ·  Fluorouracil (17)  ·  Radiation (17)  ·  Erlotinib Hydrochloride (13)  ·  Surgical Procedures, Operative (13)

Sponsors

National Cancer Institute (NCI) (73)  ·  M.D. Anderson Cancer Center (28)  ·  National Taiwan University Hospital (26)  ·  Cairo University (16)  ·  Memorial Sloan Kettering Cancer Center (14)  ·  Vanderbilt-Ingram Cancer Center (14)  ·  Roswell Park Cancer Institute (13)  ·  Tata Memorial Hospital (9)  ·  Dana-Farber Cancer Institute (8)  ·  Mayo Clinic (8)  ·  Chang Gung Memorial Hospital (7)  ·  Eastern Cooperative Oncology Group (7)  ·  Fox Chase Cancer Center (7)  ·  Shanghai Jiao Tong University School of Medicine (7)  ·  Alliance for Clinical Trials in Oncology (6)

Countries

United States (380)  ·  China (47)  ·  Canada (46)  ·  Taiwan (45)  ·  France (44)  ·  Egypt (30)  ·  India (30)  ·  Italy (24)  ·  United Kingdom (24)  ·  Netherlands (20)  ·  Germany (15)  ·  Denmark (11)  ·  Spain (9)  ·  Sweden (9)  ·  Belgium (8)

Top investigators

Barbara Murphy, MD (6)  ·  Athanassios Argiris, MD (5)  ·  Yueh-Hsia Chen, PhD (5)  ·  Chun-Pin Chiang, DMSc (4)  ·  Corey J. Langer, MD (3)  ·  Hassan Arshad, MD (3)  ·  Lai-ping Zhong, MD, PhD (3)  ·  Shin-Jung Cheng, DDS, MS, PhD (3)  ·  Yueh-Hsia Chen, Master (3)  ·  Alan Ho, MD, PhD (2)  ·  Alan L Ho (2)  ·  Ann Gillenwater (2)  ·  Ann M. Gillenwater, MD (2)  ·  Anurag Singh (2)

Results publications

PMID 12361079, PMID 12988177, PMID 15172646, PMID 15979480, PMID 18457329, PMID 20014446, PMID 20623305, PMID 21541945, PMID 22108231, PMID 22422558, PMID 22864015, PMID 23720248, PMID 24817237, PMID 34503735, PMID 39532605, PMID 39584361, PMID 10071296, PMID 10772298, PMID 11754498, PMID 12625522, PMID 15459926, PMID 19260131, PMID 20299249, PMID 21537629, PMID 21794962, PMID 22947240, PMID 23358022, PMID 23431215, PMID 23996343, PMID 24478217, PMID 24658376, PMID 24909649, PMID 25057165, PMID 25224592, PMID 25229260, PMID 25613348, PMID 25931658, PMID 26027881, PMID 31838007, PMID 37650478, PMID 40086048, PMID 40341199, PMID 10459885, PMID 10646723, PMID 11246687, PMID 11246689, PMID 11308246, PMID 11784253, PMID 11841126, PMID 11914437

NIH funding

P30CA068485 (10), P30CA016672 (8), U10CA180868 (7), P30CA006516 (6), P30CA023074 (5), U10CA180820 (5), U10CA021115 (4), U10CA031946 (4), U10CA032102 (4), 2015 (3), N01CM62201 (3), P30CA006927 (3), P30CA014520 (3), P30CA014599 (3), P30CA043703 (3)